MARKET

CHRS

CHRS

Coherus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.45
+0.33
+2.05%
After Hours: 16.45 0 0.00% 16:00 04/08 EDT
OPEN
16.49
PREV CLOSE
16.12
HIGH
16.56
LOW
15.63
VOLUME
707.87K
TURNOVER
--
52 WEEK HIGH
23.91
52 WEEK LOW
10.86
MARKET CAP
1.17B
P/E (TTM)
14.16
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CHRS stock price target is 31.57 with a high estimate of 35.00 and a low estimate of 27.00.

EPS

CHRS News

More
  • The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products
  • Zacks · 4h ago
  • Signs of Coronavirus Slowdown Pep Up Wall Street: 5 Winners
  • Zacks · 1d ago
  • Is Coherus BioSciences (CHRS) Stock a Solid Choice Right Now?
  • Zacks · 03/26 13:34
  • Selloff creating bargains in healthcare - Baird
  • seekingalpha · 03/25 22:54

Industry

Biotechnology & Medical Research
+3.24%
Pharmaceuticals & Medical Research
+3.09%

Hot Stocks

Symbol
Price
%Change

About CHRS

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.
More

Webull offers kinds of Coherus Biosciences Inc stock information, including NASDAQ:CHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHRS stock news, and many more online research tools to help you make informed decisions.